Drugs / YPEG-rhGH
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT05838885 | Feb 2022 → Oct 2023 | Turner syndrome, fetal growth restriction, isolated short stature | Xiamen Amoytop Biotech Co., Ltd. | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | YPEG-rhGH | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05838885 ↗ |
| Modality | Protein / enzyme biologic | “Y- Shaped Pegylated Recombinant Growth Hormone (YPEG-rhGH)” NCT05838885 ↗ |
| Route | Subcutaneous | “YPEG-rhGH, 140μg/kg, s.c., once a week, for 52 weeks” NCT05838885 ↗ |